Navigation Links
Anesiva Appoints Daniel Janney to Board of Directors
Date:2/8/2008

chievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: the timing and results of our clinical trials, whether Anesiva is able to manufacture its products on commercially reasonable terms and the degree to which Zingo gains market acceptance. Actual results may differ materially from those contained in the forward-looking statements in this press release. Additional information concerning these and other risk factors is contained in Anesiva's quarterly report on Form 10-Q for the quarter ended September 30, 2007.

Anesiva undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.


'/>"/>
SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
2. Anesiva Announces Completion of Common Stock Offering
3. Anesiva Raises $45 Million in Common Stock Offering
4. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
7. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
8. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
9. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
10. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
11. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals ... APTIOM TM (eslicarbazepine acetate) for use as a ... in patients with epilepsy who are not satisfactorily controlled ... for use in patients under 18 years of age. ... common neurological disorders and according to Epilepsy Canada, it ...
(Date:7/10/2014)... July 10, 2014 Deep Knowledge ... Medicine Forum on ‘Commercialising Longevity Research’ and welcomed ... to the London Bioscience Innovation Center for the ... and Aging Analytics Ltd. The meeting highlighted the ... translational research for age-related disease, as well as ...
(Date:7/10/2014)... 2014 OMICS Group’s 5th International conference ... August, 2014 at Double Tree by Hilton Beijing, China ... in Analytical & Bioanalytical research methods only to facilitate ... this occasion, Dr. Srinubabu Gedela, MD of OMICS Group ... a remarkable one in bringing a unique and international ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a firm ... today announced that it has acquired the Slim-Fast brand ... the business. Terms of the transaction were not disclosed. ... meal replacement business that markets ready-to-drink shakes, powders, bars ... America and in the United ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2
... industry news rags was making a big deal this week ... tag manufacture. Almost as a throw-away comment, the article mentioned ... 20 percent. , ,The tag manufacturer was suggesting other ... crunched when the paper was rolled up to tightly. ...
... -- The NeuronFarm, a developer of Web-based ... announced the immediate availability of its flagship product, ... skills in third through eighth graders in several ... It uses automated text scoring, engaging simulations and ...
... I.B.I.S., Inc. of Norcoss, Ga., will offer the Microsoft ... Systems in the metro Atlanta area, the two ... offers a variety of public classes from end user applications ... , , Saint Michael's Hospital in Stevens Point and ...
Cached Biology Technology:The more things change ... 2The more things change ... 3NeuronFarm's 3D-Reader ready to ship 2Tech Digest: Inacom; St. Michael's, St. Clare's hospitals; Merge eMed; Advanced Data-Comm; Blue Cross and Blue Shield 2
(Date:7/10/2014)... June 27, 2014  Pomerantz LLP has filed ... ("Provectus" or the "Company")(NYSE-MKT: PVCT) and certain of ... States District Court, Middle District of ... of a class consisting of all persons or ... between December 17, 2013 and May 22, 2014, ...
(Date:7/10/2014)... 2, 2014 It is a great honor ... appointment of the world-renowned Thoracic and Cardiovascular surgeon, Mark ... Dr. Ginsburg, with over 34 years of experience, ... and Good Samaritan Regional Medical Center. Dr. Ginsburg has ... 1980,s and is considered an expert in the implantation ...
(Date:7/10/2014)... , July 7, 2014 Fingerprint ... first major design win (DW). A Chinese Top 5 smartphone ... planned start of mass production in October 2014.   ... Chinese Top 5 smartphone OEM, which has a planned date ... a target sales volume for this phone of 3 million ...
Breaking Biology News(10 mins):SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2
... the first time, physicians at University Health Network and ... genes that can predict whether a patient with chronic ... treatments. , These genes could also become the basis ... predict which patients will respond to therapy. , The ...
... will allow University of Oregon scientists to replicate an ... test and understand the human body's response to everyday ... a 12-foot-square room capable of simulating altitude up to ... between 14 and 122 degrees Fahrenheit, and controlling humidity ...
... in the UK have proved that human embryonic stem cells ... cells that eventually become eggs or sperm. Their work opens ... from stem cells and used for assisted reproduction, therapeutic cloning ... and for the improved treatments for patients suffering from a ...
Cached Biology News:Identification of specific genes predicts which patients will respond to Hepatitis C treatment 2Identification of specific genes predicts which patients will respond to Hepatitis C treatment 3Going To Extremes To Improve Human Health 2Human embryonic stem cells have the potential to develop into eggs and sperm in the laboratory 2Human embryonic stem cells have the potential to develop into eggs and sperm in the laboratory 3
... been many modifications to the original formulas in ... still play an important role in tissue,culture. A ... and osmotic balance in the medium and to ... ions, is as valuable today as when it ...
Request Info...
... ion trap mass spectrometer enables high-throughput solutions ... LXQ linear ion trap mass spectrometer is ... delivering the fast cycle time and increased ... at an attractive price. The combination ...
... stain was developed specifically for reduced mutagenicity ... DNA in agarose or acrylamide gels. SYBR Safe ... bromide but SYBR Safe stain's detection sensitivity is ... stain comes as a premixed solution that can ...
Biology Products: